Scinai Immunotherapeutics Ltd. (SCNI) Form 6-K — Oct 16, 2026
Scinai Immunotherapeutics closed a $4.0 million financing via a private placement of 2,458,334 ADSs with Series A-1 Warrants, plus a warrant inducement exercising 879,194 ADSs at a reduced $1.20 price with additional new warrants. Proceeds will advance current CDMO customer programs, pursue additional CDMO contracts, and selectively fund the immunotherapy pipeline. The company estimates an operating runway to late 2027, potentially into 2028 if later CDMO phases are activated.
Key figures
- Guidance
- Operating runway estimated to late 2027, potentially into 2028 if later CDMO phases are activated
- Gross Proceeds
- 4000000
- Offering Price
- 1.2
- Shares Offered
- 2,458,334 ADSs (each ADS = 40,000 ordinary shares), plus warrants to purchase up to 3,687,501 ADSs; warrant inducement for 879,194 ADSs at $1.20 per ADS with new warrants for up to 1,318,791 ADSs
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.